Depression and Anxiety Trial, Recruiting NCT06399653 Sponsor: VA Office of Research and Development Condition: Depression and Anxiety
Back to Depression And Anxiety

Depression and Anxiety Trial, Recruiting

NCT06399653
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Veterans aged between 21 and 65 years, of any race or ethnicity
  • People who have been diagnosed with moderate or severe alcohol use disorder (AUD) according to standard diagnostic criteria, confirmed through a structured interview
  • People who have at least one area of daily life affected by alcohol use, currently experience cravings for alcohol, and have been drinking heavily (5 or more drinks in a day for men, or 4 or more drinks in a day for women, on 5 or more days in the past month)
  • People who experience mild to moderate withdrawal symptoms when they stop drinking
  • People who are able to go without alcohol for 12 to 24 hours without serious discomfort or medical complications
  • People who are able to follow the study schedule and procedures, and who speak English
  • People who are able to give written consent to participate before the study begins
  • People who are willing and able to use the study device (a non-invasive nerve stimulator or a sham version) as instructed throughout the study, and who are willing to attend a final return visit

Who may not be able to join:

  • People who show moderate to severe alcohol withdrawal symptoms on the day of the brain scan, based on a standard assessment tool
  • People who have had serious alcohol withdrawal complications in the past 6 months, such as seizures, hallucinations, or a condition called delirium tremens
  • People who are currently enrolled in, or have been enrolled in, an abstinence-based treatment program within the last 90 days
  • People who have shown a pattern of misusing substances other than alcohol in the month before screening
  • People who have a severe, uncontrolled psychiatric condition involving psychotic symptoms or significant difficulty with thinking and memory (note: a diagnosis of PTSD alone would not exclude someone)
  • People who are assessed as being at urgent risk of harming themselves or others
  • People who have a known neurological condition that may affect memory or thinking
  • People who have had a head injury involving more than 24 hours of unconsciousness
  • People who have a significant uncontrolled or unstable medical illness, or who have had major surgery within 1 month of the screening visit
  • People who are unable to have an MRI scan due to having a pacemaker, certain metal implants or fragments in the body, certain types of medical devices (such as a heart valve replacement or a spinal shunt), a copper intrauterine device (IUD), or who are pregnant or breastfeeding (all implants will be reviewed for safety)
  • People who have certain conditions or devices that make the neck nerve stimulation unsafe, including an implanted medical device, a metallic implant at or near the neck, significant narrowing of the carotid arteries, a history of a surgical procedure on the vagus nerve, uncontrolled blood pressure or heart rate problems, severe heart or cardiovascular disease, a history of stroke or mini-stroke (TIA), heart failure, severe coronary artery disease, or a heart attack within the past 5 years
  • People who are taking medication for alcohol use disorder must have been on a stable dose for at least 2 weeks before taking part
  • People who are currently taking opioids or benzodiazepines (a type of sedative or anxiety medication)
  • People who, during the study, are found by the research team to need a higher level of medical or psychiatric care

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Ruth Klaming, PhD, VA San Diego Healthcare System, San Diego, CA

Phone: (858) 642-3538

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 January 2025
Est. completion
31 August 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Hamilton Anxiety Rating Scale (HAM-A); Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised (CIWA-Ar); Alcohol Urge Questionnaire (AUQ); WHO Quality of Life assessment (WHOQOL-BREF)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov